Impact of elexacaftor/tezacaftor/ivacaftor on the presence of bacterial and fungal pathogens in the lower respiratory tract of children with cystic fibrosis

Setnikar Kimovec, Gaja (avtor), Seme, Katja (avtor), Matos, Tadeja (avtor), Špik, Vesna (avtor), Krivec, Uroš (avtor), Praprotnik, Marina (avtor), Rodman, Jasna (avtor)

Background: Highly effective CFTR modulator therapy, such as elexacaftor/tezacaftor/ivacaftor (ETI), has been linked to significant clinical improvements in people with cystic fibrosis (pwCF). However, its effect on the presence of respiratory pathogens in the lower respiratory tract of younger, mainly non-expectorant children with CF remains poorly understood, especially using lower airway sampling methods. We aimed to investigate changes in lower airway microbiology and clinical outcomes in children with CF aged 6-12 years before and after starting ETI. Methods: We conducted a prospective observational single-centre study including children with CF commencing ETI who had no prior exposure to CFTR modulators, inhaled antibiotics, or prophylactic antibiotics. Lower airway microbiology was assessed longitudinally using sputum or induced sputum (IS). Pathogen prevalence, sweat chloride concentration, pulmonary function, nutritional status, and rate of exacerbations were evaluated before and up to 12 months after ETI initiation. Results: Sixteen pwCF were included (median age 8.4 years, 69 % boys, 75% were F508del homozygous). None of the children was expectorant at any point during the study. Following ETI initiation, we observed decreased growth of methicillin-sensitive Staphylococcus aureus and Aspergillus fumigatus, reduced variability in fungal populations, and an increase in negative bacterial and fungal culture results. Conclusions: In this exploratory study of young, modulator-naïve children with CF, ETI initiation was associated with changes in the lower airway microbiology composition assessed by IS. These findings highlight potential shifts in lower airway microbiology and the importance of age-appropriate lower airway sampling in future paediatric studies.

• Jezik: Angleški jezik
• Ključne besede: children, cystic fibrosis, elexacaftor/tezacafot/ivacaftor, respiratory pathogens
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2026
• Št. strani: 7 str.
• Številčenje: Vol. 257, art. 108846
• PID: 20.500.12556/RUL-185260
• UDK: 616.2-053.2:577
• ISSN pri članku: 1532-3064
• DOI: 10.1016/j.rmed.2026.108846
• COBISS.SI-ID: 276097795
• Datum objave v RUL: 30.07.2026

Gradivo je del revije

• Naslov: Respiratory medicine
• Skrajšan naslov: Respir. med.
• Založnik: Elsevier
• ISSN: 1532-3064
• COBISS.SI-ID: 518761241

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: otroci, cistična fibroza, eleksakaftor/tezakafot/ivakaftor, respiratorni patogeni

Projekti

• Financer: ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
• Številka projekta: P3-0458
• Naslov: Prirojene in pridobljene okvare imunosti